These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 29024304)

  • 1. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
    Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
    Fu N; Yang S; Zhang J; Zhang P; Liang M; Cong H; Lin W; Tian F; Lu C
    Int Urol Nephrol; 2018 Jan; 50(1):105-112. PubMed ID: 29071556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Alprostadil on the Prevention of Contrast-Induced Nephropathy: A Meta-Analysis of 36 Randomized Controlled Trials.
    Xie J; Jiang M; Lin Y; Deng H; Li L
    Angiology; 2019 Aug; 70(7):594-612. PubMed ID: 30669852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
    Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
    Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive Effects of Alprostadil Against Contrast-Induced Nephropathy Inpatients With Renal Insufficiency Undergoing Percutaneous Coronary Intervention.
    Yang SC; Fu NK; Zhang J; Liang M; Cong HL; Lin WH; Tian FS; Lu CZ; Sun TT; Zhang WY; Ma ZH
    Angiology; 2018 May; 69(5):393-399. PubMed ID: 29073785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin Resistance Increases the Risk of Contrast-Induced Nephropathy in Patients Undergoing Elective Coronary Intervention.
    Li Y; Liu Y; Shi D; Yang L; Liang J; Zhou Y
    Angiology; 2016 Feb; 67(2):139-45. PubMed ID: 25843952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple risk score model for predicting contrast-induced nephropathy after coronary angiography in patients with diabetes.
    Zeng JF; Chen SQ; Ye JF; Chen Y; Lei L; Liu XQ; Liu Y; Wang Y; Lin JJ; Chen JY
    Clin Exp Nephrol; 2019 Jul; 23(7):969-981. PubMed ID: 31049747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
    Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
    Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intravenous hydration on risk of contrast induced nephropathy and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.
    Liu Y; Hong D; Wang AY; Guo R; Smyth B; Liu J; Sun G; Chen S; Tan N; Jardine M; Brieger D; Shaman A; Islam S; Chen J; Gallagher M
    BMC Cardiovasc Disord; 2019 Apr; 19(1):87. PubMed ID: 30961544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
    Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
    Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials.
    Liang M; Yang S; Fu N
    Medicine (Baltimore); 2017 Jul; 96(27):e7384. PubMed ID: 28682890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated high-sensitivity C-reactive protein combined with procalcitonin predicts high risk of contrast-induced nephropathy after percutaneous coronary intervention.
    Gu G; Yuan X; Zhou Y; Liu D; Cui W
    BMC Cardiovasc Disord; 2019 Jun; 19(1):152. PubMed ID: 31234798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
    Shehata M; Hamza M
    Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
    Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
    Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience.
    Wang Y; Zhao HW; Zhang XJ; Chen BJ; Yu GN; Hou AJ; Luan B
    BMC Cardiovasc Disord; 2019 Mar; 19(1):74. PubMed ID: 30922230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Kurtul A; Yarlioglues M; Murat SN; Demircelik MB; Acikgoz SK; Ergun G; Duran M; Cetin M; Ornek E
    Angiology; 2015 May; 66(5):433-40. PubMed ID: 24834929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of probucol on preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention].
    Suo XQ; Yang SC; Ma ZH; Sun TT; Zhang WY; Cong HL; Lin WH; Lu CZ; Tian FS; Fu NK
    Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(41):3234-3238. PubMed ID: 29141361
    [No Abstract]   [Full Text] [Related]  

  • 20. Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Chronic Total Occlusion Versus Non-Occlusive Coronary Artery Disease.
    Demir OM; Lombardo F; Poletti E; Laricchia A; Beneduce A; Maccagni D; Slavich M; Giannini F; Carlino M; Margonato A; Cappelletti A; Colombo A; Azzalini L
    Am J Cardiol; 2018 Dec; 122(11):1837-1842. PubMed ID: 30292337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.